Roche's Tecentriq cocktail adds to lung cancer survival success
ZURICH (Reuters) - Roche's Tecentriq immunotherapy combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.
from Reuters: Health News https://reut.rs/2ITBooc
http://bit.ly/2zwRqiM